ACR20 and PsARC responder rate at week 12 by concomitant use of DMARDs at baseline
| Baseline DMARD status | Placebo n=136 % (n) | CZP 200 mg Q2W n=138 % (n) | CZP 400 mg Q4W n=135 % (n) |
|---|---|---|---|
| ACR20 | |||
| Concomitant DMARD | 28.4 (25/88) | 58.6 (58/99) | 55.0 (55/100) |
| No concomitant DMARDs | 16.7 (8/48) | 56.4 (22/39) | 42.9 (15/35) |
| PsARC | |||
| Concomitant DMARD | 42.0 (37/88) | 73.7 (73/99) | 63.0 (63/100) |
| No concomitant DMARDs | 31.3 (15/48) | 71.8 (28/39) | 74.3 (26/35) |
ACR, American College of Rheumatology; CZP, certolizumab pegol; DMARDs, disease modifying antirheumatic drugs; PsARC, psoriatic arthritis response criteria; Q2W, every 2 weeks; Q4W, every 4 weeks; permitted concomitant DMARDs were methotrexate (MTX, up to 25 mg/week), sulfasalazine (SSZ, up to 3 g/day), and leflunomide (LEF, up to 20 mg/day).